Pyruvate dehydrogenase E1-alpha deficiency
MONDO:0010717Pyruvate dehydrogenase E1-alpha deficiency is the most frequent form of pyruvate dehydrogenase deficiency (PDHD) characterized by variable lactic acidosis, impaired psychomotor development, hypotonia and neurological dysfunction.
Also known as: pyruvate decarboxylase deficiency, PDHAD, pyruvate dehydrogenase E1-alpha deficiency, pyruvate dehydrogenase complex E1 component subunit alpha deficiency, pyruvate dehydrogenase e1-alpha deficiency, X-linked dominant, PDH deficiency, ataxia with lactic acidosis 1, ataxia, intermittent, with abnormal pyruvate metabolism
22 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control TerminatedThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase: PHASE2, PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
Knowledge-focused TerminatedThis study measures levels of a protein called NT-3 in the blood of people with peripheral neuropathy or Charcot-Marie-Tooth disease. Researchers will compare these levels with measures of muscle strength, mobility, and daily function. The goal is to see whether NT-3 levels corre…
Sponsor: Zarife Sahenk • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC